- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02767310
Study to Determine the Bioequivalence of Two Products Containing Rosuvastatin (20 mg/Tablet)
July 4, 2016 updated by: Verisfield UK Ltd. Greek Branch
A Pivotal, Open-label, Balanced, Randomised, Two-treatment, Two-sequence, Two-period, Two-way Crossover, Single Oral Dose Bioequivalence Study of Rosuvastatin/ Verisfield 20 mg Film-coated Tablets Versus Crestor/ AstraZeneca 20 mg Film-coated Tablets in Healthy Adults Under Fasting Conditions
The purpose of this study is to determine the bioequivalence of Rosuvastatin/ Verisfield 20 mg film-coated tablets and Crestor™/ AstraZeneca 20 mg film-coated tablets.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study aims to compare the absorption and disposition kinetics of two products containing rosuvastatin under fasting conditions.
These products are: Rosuvastatin/ Verisfield 20 mg film-coated tablets, a Test product manufactured by HELP S.A., Greece and Crestor™/ AstraZeneca 20 mg film-coated tablets, a Reference product manufactured by AstraZeneca, UK.
The bioequivalence of a single 20 mg dose of both products will be assessed by comparing the pharmacokinetic parameters derived from the plasma concentration-time profiles for rosuvastatin.
Study Type
Interventional
Enrollment (Actual)
49
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Gujarat
-
Ahmedabad, Gujarat, India, 380056
- Synchron Research Services Pvt. Ltd.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 43 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Willingness to provide informed consent to participate in the study.
- Comprehension of the nature and purpose of the study and willingness to comply with the requirements of the entire procedure.
- Healthy adult, human Indian volunteers within the age range of 18 to 45 years (both inclusive).
- Body Mass Index (BMI) ≥ 18.50 kg/m2 to ≤ 30.00 kg/m2.
- Hemoglobin: ≥12.0 gm% for male and ≥11.5 gm% for female.
- Absence of disease markers of HIV I & II, HBsAg, HCVAb and P24 antigen test.
- Females of childbearing age must be practicing an acceptable form of birth control for at least six months before screening, unless they have had bilateral oophorectomy or tubal ligation or their male partner has had vasectomy.
- Females of childbearing age agree to use acceptable form of birth control during the study and until the drug is washed out from the body, i.e. at least 14 days after last dosing, unless they have had bilateral oophorectomy or tubal ligation or their male partner has had vasectomy.
- Absence of significant disease or clinically significant abnormal laboratory values during the laboratory evaluations.
- Absence of any diseases in medical history or physical examination during the screening.
- Have a normal 12-lead ECG or one with abnormality considered clinically insignificant.
- Have a normal chest X-ray (P. A. view).
- Non smokers (since last six months)
- Negative serum β-HCG at the time of screening (for females only)
Exclusion Criteria:
- History / evidence of allergy or hypersensitivity to rosuvastatin or to any of the excipients or to any other drug.
- Any major illness within the last three months or any significant ongoing chronic medical illness.
- History of or active liver or kidney disease.
- History of or active deep vein thrombosis and thromboembolic disorders.
- History of breast cancer, endometrial cancer or other estrogen-dependent neoplasia, endometriosis and undiagnosed vaginal bleeding (for females only).
- History of drug abuse (including barbiturates, benzodiazepines, opioids, cocaine, cannabinoids and amphetamine etc.) within the last three months.
- History of neuropsychiatric diseases.
- History of hypothyroidism.
- Personal or family history of hereditary muscular disorders.
- History of myopathy.
- History of myalgia.
- History of rhabdomyolysis.
- History of alcohol abuse.
- History of proteinuria.
- Asian population (except Indian).
- History of interstitial lung disease.
- History of or current gastro-intestinal diseases influencing drug absorption.
- History of alcoholism (more than two years), moderate drinkers (more than three drinks per day).
- Participation in any clinical trial within last three months.
- History of difficulty with donating blood or difficulty in accessibility of veins in left or right arm.
- Donation of blood (one unit or 350 mL or more) within last three months.
- Use of any prescription drug therapy within last two weeks and over the counter (OTC) drugs or herbal products within last one week.
- Pregnant women.
- Breast feeding women.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Test Product
Rosuvastatin 20 mg film-coated tablets
|
Single oral dose of 20 mg
|
Active Comparator: Reference product
Crestor 20 mg film-coated tablets
|
Single oral dose of 20 mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area under the plasma concentration (AUC0-t) from zero (0) hours to time (t)
Time Frame: Before dosing (0 hour) and 0.25, 0.50, 0.75, 1.00, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00 and 48.00 hours post-dose
|
The area under the plasma concentration versus time curve, from time zero (0) to t hours
|
Before dosing (0 hour) and 0.25, 0.50, 0.75, 1.00, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00 and 48.00 hours post-dose
|
Maximum concentration (Cmax)
Time Frame: Before dosing (0 hour) and 0.25, 0.50, 0.75, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00 and 48.00 hours post-dose
|
Maximum measured plasma concentration
|
Before dosing (0 hour) and 0.25, 0.50, 0.75, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00 and 48.00 hours post-dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to maximum concentration (Tmax)
Time Frame: Before dosing (0 hour) and 0.25, 0.50, 0.75, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00 and 48.00 hours post-dose
|
Time of the maximum measured plasma concentration.
If the maximum value occurs at more than one time point, tmax is defined as the first time point with this value
|
Before dosing (0 hour) and 0.25, 0.50, 0.75, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00 and 48.00 hours post-dose
|
Elimination rate constant (Kel)
Time Frame: Before dosing (0 hour) and 0.25, 0.50, 0.75, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00 and 48.00 hours post-dose
|
Apparent first-order elimination or terminal rate constant
|
Before dosing (0 hour) and 0.25, 0.50, 0.75, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00 and 48.00 hours post-dose
|
Terminal half life (t1/2)
Time Frame: Before dosing (0 hour) and 0.25, 0.50, 0.75, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00 and 48.00 hours post-dose
|
The elimination or terminal half-life
|
Before dosing (0 hour) and 0.25, 0.50, 0.75, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00 and 48.00 hours post-dose
|
Area under the plasma concentration (AUC0-infinity) from zero (0) hours to infinity
Time Frame: Before dosing (0 hour) and 0.25, 0.50, 0.75, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00 and 48.00 hours post-dose
|
The area under the plasma concentration versus time curve from time (0) to infinity
|
Before dosing (0 hour) and 0.25, 0.50, 0.75, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00 and 48.00 hours post-dose
|
Number of participants with Adverse Events
Time Frame: 6 days
|
6 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Kathiria Jayesh, M.D., Synchron Research Services Pvt. Ltd.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2016
Primary Completion (Actual)
June 1, 2016
Study Completion (Actual)
June 1, 2016
Study Registration Dates
First Submitted
May 9, 2016
First Submitted That Met QC Criteria
May 9, 2016
First Posted (Estimate)
May 10, 2016
Study Record Updates
Last Update Posted (Estimate)
July 6, 2016
Last Update Submitted That Met QC Criteria
July 4, 2016
Last Verified
May 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ROS/2016/1278
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Rosuvastatin 20 mg film-coated tablets
-
Valenta Pharm JSCCompletedInfluenza, Human | Common Cold | Acute Respiratory InfectionRussian Federation
-
Future University in EgyptCompleted
-
Valenta Pharm JSCCompletedInfluenza, Human | Common Cold | Acute Respiratory InfectionRussian Federation
-
AbbottRecruitingFunctional DyspepsiaMalaysia, Armenia
-
Boehringer IngelheimCompleted
-
Chong Kun Dang PharmaceuticalCompletedDyslipidemiasKorea, Republic of
-
Bionorica SECompletedPremenstrual Syndrome | Cyclic MastodyniaCzech Republic
-
Damanhour UniversityCompleted
-
Fundacion Clinic per a la Recerca BiomédicaActive, not recruiting